Each year, the American Society of Bone & Mineral Research (ASBMR) holds a scientific meeting for researchers to present their latest findings in bone research. More than 3,000 scientists from around the world attend this important research meeting.

This year, at the 2022 ASBMR Annual Meeting, early diagnosis of FOP was the focus of a symposium supported by both Ipsen and BioCryst Pharmaceuticals. FOP clinical trial recruitment was also the focus of a panel presentation during a pre-meeting program "Rare Diseases: From Molecules and Mechanisms to Therapeutics."

There were two other oral presentations on heterotopic ossification (HO) and FOP and 14 posters were presented. We would like to congratulate the researchers who had their abstract or presentation accepted by the ASBMR, see below. The 2022 ASBMR meeting was held in Austin, Texas, USA, from September 9 to 12.

ORAL PRESENTATIONS

Mona Al Mukaddam, MD and Robert Pignolo, MD, PhD
University of Pennsylvania and Mayo Clinic
Fibrodysplasia Ossificans Progressiva (FOP): Improving Outcomes with Early Diagnosis (Symposium supported by BioCryst Pharmaceuticals and Ipsen)

Michelle Davis
IFOPA, United States
Engaging diverse communities in rare bone disease research

Heeseog Kang, PhD
University of Texas Southwestern Medical Center, United States
HIF1-α promotes heterotopic ossification via metabolic reprogramming and collagen extracellular matrix organization

Eileen Shore, PhD
University of Pennsylvania, United States
New research on FOP disease pathogenesis and therapeutic strategies

POSTERS

Mona Al Mukaddam, MD, MS, CCD
University of Pennsylvania, United States
Joint function and quality of life in fibrodysplasia ossificans progressiva: Results from an international Burden of Illness Survey of patients and family members

Robyn Allen, PhD
University of Pennsylvania, United States
Altered GS domain mechanics by the fibrodysplasia ossificans progressiva mutant ACVR1 receptor reduces regulatory constraints on BMP pathway signaling

Xilin Chen, PhD
BioCryst Pharmaceuticals, United States
Preclinical characterization of BCX9250, a potent oral Activin receptor-like kinase-2 (ALK2) Inhibitor, for the treatment of fibrodysplasia ossificans progressiva

Matthew Davidson, PharmD
BioCryst Pharmaceuticals, United States
Pharmacokinetics and safety of BCX9250, an ALK2 inhibitor for the potential treatment of fibrodysplasia ossificans progressiva, following and multiple doses of BCX9250 in healthy subjects

Alexander Farid
Boston Children's Hospital, United States
Non-invasive, at-home assessment of muscle tissue integrity in patients with fibrodysplasia ossificans progressiva using Electrical Impedance Myography

Negar Karimian, MD, MSc, PhD
Ipsen
IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva: Methodology of the Randomized, Double-Blind, Placebo-Controlled Phase II FALKON Trial

Takenobu Katagiri, PhD
Saitama Medical University, Japan
Mutated ALK2 associated with genetic skeletal disorders facilitate hyper-assembly of ALK2 dimers and induce pathological signaling

Robert Pignolo, MD, PhD
Mayo Clinic, United States
Association of Heterotopic Ossification with Use of Aids, Assistive Devices, and Adaptations in Individuals with Fibrodysplasia Ossificans Progressiva

S. Christy Rohani-Montez
Medscape Education Global, United Kingdom
Independent medical education on fibrodysplasia ossificans progressiva significantly improves knowledge of guideline-based diagnosis and management

Ruben de Ruiter, MSc
Amsterdam University Medical Center, The Netherlands
TNF-α, IL-6 and TGF-β induce Activin A production in dermal fibroblasts of fibrodysplasia ossificans progressiva patients

Christiaan Scott, MBChB, FCPaed (SA)
University of Cape Town, South Africa
The Diagnostic Odyssey: Lessons from Tin Soldiers and the search for undiagnosed individuals with Fibrodysplasia Ossificans Progressiva (FOP)

Bernard Smilde, MD
Amsterdam University Medical Center
Saracatinib Prevents Phosphorylation of SMAD 1/5/9 in Periodontal Ligament and Dermal Fibroblast Cells of FOP Patients Following Activin A Treatment

Sho Tsukamoto, PhD
Saitama Medical University, Japan
Establishment of a mouse model of human fibrodysplasia ossificans progrssiva

Xiaobing Yu, MD
University of California, San Francisco, United States
Active ACVR1 signaling in sensory neurons contributes to neuropathic pain in patients with fibrodysplasia ossificans progressiva
Saracatinib Prevents Phosphorylation of SMAD 1/5/9 in Periodontal Ligament and Dermal Fibroblast Cells of FOP Patients Following Activin A Treatment